Eicosanoids in the gastrointestinal tract
Eicosanoids play important roles in modulating inflammation throughout the body. The gastrointestinal (GI) tract, in part because of its intimate relationship with the gut microbiota, is in a constant state of low‐grade inflammation. Eicosanoids like PGs, lipoxins and leukotrienes play essential rol...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 2019-04, Vol.176 (8), p.1000-1008 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1008 |
|---|---|
| container_issue | 8 |
| container_start_page | 1000 |
| container_title | British journal of pharmacology |
| container_volume | 176 |
| creator | Wallace, John L |
| description | Eicosanoids play important roles in modulating inflammation throughout the body. The gastrointestinal (GI) tract, in part because of its intimate relationship with the gut microbiota, is in a constant state of low‐grade inflammation. Eicosanoids like PGs, lipoxins and leukotrienes play essential roles in maintenance of mucosal integrity. On the other hand, in some circumstances, these mediators can become major drivers of inflammatory processes when the lining of the GI tract is breached. Drugs such as nonsteroidal anti‐inflammatories, by altering the production of various eicosanoids, can dramatically impact the ability of the GI tract to respond appropriately to injury. Disorders such as inflammatory bowel disease appear to be driven in part by altered production of eicosanoids. Several classes of drugs have been developed that target eicosanoids.
Linked Articles
This article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc |
| doi_str_mv | 10.1111/bph.14178 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6451073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2296299257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4438-b79640f3af2f687f451fe5b3f896cfd32ba815426f0068a7348a639abe60a1f53</originalsourceid><addsrcrecordid>eNp1kM1OAjEURhujEUQXvoAhccVioP_tbEyUoJiQ6ELXTWdooWSYYjtoeHurg0QXdnMX9-R8vR8AlwgOUXqjYrMcIoqEPAJdRAXPGJHoGHQhhCJDSMoOOItxBWFaCnYKOjinknGJumAwcaWPuvZuHvuu7jdL01_o2ATv6sbExtW66jdBl805OLG6iuZiP3vg9X7yMp5ms6eHx_HtLCspJTIrRM4ptERbbLkUljJkDSuIlTkv7ZzgQkvEKOYWQi61IFRqTnJdGA41soz0wE3r3WyLtZmXpk7xldoEt9Zhp7x26u-mdku18O-KpygoSBJc7wXBv23TDWrltyHdERXGOcd5jplI1KClyuBjDMYeEhBUX62q1Kr6bjWxV7-_dCB_akzAqAU-XGV2_5vU3fO0VX4ChciA4w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2296299257</pqid></control><display><type>article</type><title>Eicosanoids in the gastrointestinal tract</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wallace, John L</creator><creatorcontrib>Wallace, John L</creatorcontrib><description>Eicosanoids play important roles in modulating inflammation throughout the body. The gastrointestinal (GI) tract, in part because of its intimate relationship with the gut microbiota, is in a constant state of low‐grade inflammation. Eicosanoids like PGs, lipoxins and leukotrienes play essential roles in maintenance of mucosal integrity. On the other hand, in some circumstances, these mediators can become major drivers of inflammatory processes when the lining of the GI tract is breached. Drugs such as nonsteroidal anti‐inflammatories, by altering the production of various eicosanoids, can dramatically impact the ability of the GI tract to respond appropriately to injury. Disorders such as inflammatory bowel disease appear to be driven in part by altered production of eicosanoids. Several classes of drugs have been developed that target eicosanoids.
Linked Articles
This article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.14178</identifier><identifier>PMID: 29485681</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Eicosanoids ; Eicosanoids - metabolism ; Gastrointestinal Microbiome - drug effects ; Gastrointestinal Microbiome - physiology ; Gastrointestinal tract ; Gastrointestinal Tract - drug effects ; Gastrointestinal Tract - metabolism ; Humans ; Inflammatory bowel diseases ; Inflammatory Bowel Diseases - metabolism ; Inflammatory Bowel Diseases - microbiology ; Inflammatory diseases ; Intestinal microflora ; Intestine ; Leukotrienes ; Microbiota ; Mucosa ; Review ; Themed Section: Review</subject><ispartof>British journal of pharmacology, 2019-04, Vol.176 (8), p.1000-1008</ispartof><rights>2018 The British Pharmacological Society</rights><rights>2018 The British Pharmacological Society.</rights><rights>2019 The British Pharmacological Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4438-b79640f3af2f687f451fe5b3f896cfd32ba815426f0068a7348a639abe60a1f53</citedby><cites>FETCH-LOGICAL-c4438-b79640f3af2f687f451fe5b3f896cfd32ba815426f0068a7348a639abe60a1f53</cites><orcidid>0000-0002-4853-1682</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451073/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451073/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1416,1432,27923,27924,45573,45574,46408,46832,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29485681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wallace, John L</creatorcontrib><title>Eicosanoids in the gastrointestinal tract</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Eicosanoids play important roles in modulating inflammation throughout the body. The gastrointestinal (GI) tract, in part because of its intimate relationship with the gut microbiota, is in a constant state of low‐grade inflammation. Eicosanoids like PGs, lipoxins and leukotrienes play essential roles in maintenance of mucosal integrity. On the other hand, in some circumstances, these mediators can become major drivers of inflammatory processes when the lining of the GI tract is breached. Drugs such as nonsteroidal anti‐inflammatories, by altering the production of various eicosanoids, can dramatically impact the ability of the GI tract to respond appropriately to injury. Disorders such as inflammatory bowel disease appear to be driven in part by altered production of eicosanoids. Several classes of drugs have been developed that target eicosanoids.
Linked Articles
This article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc</description><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Eicosanoids</subject><subject>Eicosanoids - metabolism</subject><subject>Gastrointestinal Microbiome - drug effects</subject><subject>Gastrointestinal Microbiome - physiology</subject><subject>Gastrointestinal tract</subject><subject>Gastrointestinal Tract - drug effects</subject><subject>Gastrointestinal Tract - metabolism</subject><subject>Humans</subject><subject>Inflammatory bowel diseases</subject><subject>Inflammatory Bowel Diseases - metabolism</subject><subject>Inflammatory Bowel Diseases - microbiology</subject><subject>Inflammatory diseases</subject><subject>Intestinal microflora</subject><subject>Intestine</subject><subject>Leukotrienes</subject><subject>Microbiota</subject><subject>Mucosa</subject><subject>Review</subject><subject>Themed Section: Review</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1OAjEURhujEUQXvoAhccVioP_tbEyUoJiQ6ELXTWdooWSYYjtoeHurg0QXdnMX9-R8vR8AlwgOUXqjYrMcIoqEPAJdRAXPGJHoGHQhhCJDSMoOOItxBWFaCnYKOjinknGJumAwcaWPuvZuHvuu7jdL01_o2ATv6sbExtW66jdBl805OLG6iuZiP3vg9X7yMp5ms6eHx_HtLCspJTIrRM4ptERbbLkUljJkDSuIlTkv7ZzgQkvEKOYWQi61IFRqTnJdGA41soz0wE3r3WyLtZmXpk7xldoEt9Zhp7x26u-mdku18O-KpygoSBJc7wXBv23TDWrltyHdERXGOcd5jplI1KClyuBjDMYeEhBUX62q1Kr6bjWxV7-_dCB_akzAqAU-XGV2_5vU3fO0VX4ChciA4w</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Wallace, John L</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4853-1682</orcidid></search><sort><creationdate>201904</creationdate><title>Eicosanoids in the gastrointestinal tract</title><author>Wallace, John L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4438-b79640f3af2f687f451fe5b3f896cfd32ba815426f0068a7348a639abe60a1f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Eicosanoids</topic><topic>Eicosanoids - metabolism</topic><topic>Gastrointestinal Microbiome - drug effects</topic><topic>Gastrointestinal Microbiome - physiology</topic><topic>Gastrointestinal tract</topic><topic>Gastrointestinal Tract - drug effects</topic><topic>Gastrointestinal Tract - metabolism</topic><topic>Humans</topic><topic>Inflammatory bowel diseases</topic><topic>Inflammatory Bowel Diseases - metabolism</topic><topic>Inflammatory Bowel Diseases - microbiology</topic><topic>Inflammatory diseases</topic><topic>Intestinal microflora</topic><topic>Intestine</topic><topic>Leukotrienes</topic><topic>Microbiota</topic><topic>Mucosa</topic><topic>Review</topic><topic>Themed Section: Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wallace, John L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wallace, John L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eicosanoids in the gastrointestinal tract</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2019-04</date><risdate>2019</risdate><volume>176</volume><issue>8</issue><spage>1000</spage><epage>1008</epage><pages>1000-1008</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Eicosanoids play important roles in modulating inflammation throughout the body. The gastrointestinal (GI) tract, in part because of its intimate relationship with the gut microbiota, is in a constant state of low‐grade inflammation. Eicosanoids like PGs, lipoxins and leukotrienes play essential roles in maintenance of mucosal integrity. On the other hand, in some circumstances, these mediators can become major drivers of inflammatory processes when the lining of the GI tract is breached. Drugs such as nonsteroidal anti‐inflammatories, by altering the production of various eicosanoids, can dramatically impact the ability of the GI tract to respond appropriately to injury. Disorders such as inflammatory bowel disease appear to be driven in part by altered production of eicosanoids. Several classes of drugs have been developed that target eicosanoids.
Linked Articles
This article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>29485681</pmid><doi>10.1111/bph.14178</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4853-1682</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2019-04, Vol.176 (8), p.1000-1008 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6451073 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Wiley Online Library All Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - pharmacology Eicosanoids Eicosanoids - metabolism Gastrointestinal Microbiome - drug effects Gastrointestinal Microbiome - physiology Gastrointestinal tract Gastrointestinal Tract - drug effects Gastrointestinal Tract - metabolism Humans Inflammatory bowel diseases Inflammatory Bowel Diseases - metabolism Inflammatory Bowel Diseases - microbiology Inflammatory diseases Intestinal microflora Intestine Leukotrienes Microbiota Mucosa Review Themed Section: Review |
| title | Eicosanoids in the gastrointestinal tract |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T16%3A32%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eicosanoids%20in%20the%20gastrointestinal%20tract&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Wallace,%20John%20L&rft.date=2019-04&rft.volume=176&rft.issue=8&rft.spage=1000&rft.epage=1008&rft.pages=1000-1008&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.14178&rft_dat=%3Cproquest_pubme%3E2296299257%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2296299257&rft_id=info:pmid/29485681&rfr_iscdi=true |